Investment giant KKR & Co. Inc. (NYSE:KKR) is advising investors to look past the crowded trades of the U.S. large-cap market for the next phase of growth.In its “High Grading” Outlook for 2026, the firm argues that while the S&P 500 valuations appear stretched, significant opportunity remains fo... Read more
Benzinga - Dec 24
State Street SPDR S&P Biotech ETF (NYSE:XBI) has outperformed the market over the past 20 years by 1.76% on an annualized basis producing an average annual return of 10.68%. Currently, State Street SPDR S&P Biotech ETF has a market capitalization of $8.23 billion. Buying ...Full story available o... Read more
Benzinga - Dec 23
Citi sees shares of Ligand Pharmaceuticals soaring another 46% on top of an already impressive year-to-date rally. Read more
Cnbc - Dec 09
This article is based on TheStreet’s Stock & Markets Podcast. Hosted by Chris Versace, the veteran Wall Street investor and lead portfolio manager for TheStreet Pro, the weekly podcasts are available early to members of TheStreetPro investing club. The key word here is “humane.” Michael Breen, ... Read more
Thestreet - Dec 08
While everyone's watching AI reshape chipmakers and tech sectors, the most profound transformation may be unfolding where no one’s looking: biotech. Artificial intelligence is quietly powering the biggest rally in biotech stocks since the early 2000s — and it's not hype, it’s math. The iShares Bi... Read more
Benzinga - Nov 25
A federal commission is calling for significant changes to the way the U.S. government funds and assesses scientific research. Read more
Stat - Nov 25
David Keller breaks down the technicals on this biotech giant. Read more
Cnbc - Nov 20
Demand for the company's core product has long since faded, and sales for the product took an additional hit after the termination of a distribution partnership with Fosun PharmaKey Takeaways:Genuine Biotech generated only 9 million yuan in the first half of this year from Azvudine after regainin... Read more
Benzinga - Nov 20
Europe continues to contribute to global innovation across several industries.Skype, Airbus, and BioNTech highlight the region’s strategic approach to progress.Emphasis remains on collaboration, regulation, and societal impact for long-term gains. Read more
News Linker - Nov 18
Moleculin Biotech, Inc. (NASDAQ:MBRX – Get Free Report)’s stock price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $0.46 and traded as low as $0.4262. Moleculin Biotech shares last traded at $0.4338, with a volume of 1,285,246 shares.... Read more
The Lincolnian Online - Nov 16
